SIGNIFICANT ACCOUNTING POLICIES (Details) $ / shares in Units, $ in Millions	1 Months Ended	3 Months Ended			6 Months Ended		18 Months Ended
	Jun. 18, 2013 USD ($)	Jun. 30, 2015 USD ($) $ / shares shares	Jun. 30, 2014 $ / shares shares	Dec. 31, 2009 USD ($)	Jun. 30, 2015 USD ($) item $ / shares shares	Jun. 30, 2014 $ / shares shares	Jun. 30, 2015 USD ($) $ / shares
Significant Accounting Policies [Line Items]
Number of Subsidiaries | item					2
Common stock, par value per share | $ / shares		$ 0.001	$ 0.001		$ 0.001	$ 0.001	$ 0.001
Options to purchase common stock not included in diluted LPS because the effect would be anti-dilutive | shares		20,167,947	18,778,154		19,780,594	18,844,777
Brazil Agreement [Member] | Protalix Ltd. [Member] | Fiocruz [Member]
Significant Accounting Policies [Line Items]
Revenue from selling products							$ 6.6
Supply commitment per year	$ 40.0
Purchase order received							9.2
License and supply agreement potential future payment	12.5
Supply commitment for entitled rights to be received	$ 280.0
Additional purchase amount by July 31, 2015		$ 30.0			$ 30.0		30.0
Percentage of adult Gaucher patients in Brazil currently treated with Uplyso					10.00%
Pfizer Agreement [Member]
Significant Accounting Policies [Line Items]
Pfizer Agreement, upfront payment received				$ 60.0
Pfizer Agreement [Member] | Upon FDAApproval [Member]
Significant Accounting Policies [Line Items]
Pfizer Agreement, milestone payment amount		$ 30.0			$ 30.0		$ 30.0
Pfizer Agreement [Member] | Pfizer Incorporation [Member]
Significant Accounting Policies [Line Items]
Pfizer Agreement, future revenues and expense sharing percentage		60.00%			60.00%		60.00%
Pfizer Agreement [Member] | Protalix Bio Therapeutics Incorporation [Member]
Significant Accounting Policies [Line Items]
Pfizer Agreement, future revenues and expense sharing percentage		40.00%			40.00%		40.00%